SCHEMBL30689463

SCHEMBL30689463

CO[C@H]1[C@@H](OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](O)[C@@H]2O)[C@H](n2cnc3c(N)ncnc32)O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2c[n+](C)c3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RNASEL Q05823 8/20 0.61
P2RY1 P47900 4/20 0.59
P2RY2 P41231 2/20 0.59
SRC P12931 1/20 0.59
P2RX1 P51575 1/20 0.59
P2RX3 P56373 1/20 0.59
P2RX4 Q99571 1/20 0.59
P2RX2 Q9UBL9 1/20 0.59
ALDH1A1 P00352 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
FUT5 Q11128 1/20 0.57
TGM2 P21980 1/20 0.57
MACROD2 A1Z1Q3 1/20 0.56
SIRT6 Q8N6T7 1/20 0.56
MACROD1 Q9BQ69 1/20 0.56
TRPM2 O94759 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25583996 0.98 RNASEL (0.61) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL26331783 0.98 RNASEL (0.61) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL25895037 0.98 RNASEL (0.61) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL27410758 0.98 RNASEL (0.61) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL25896437 0.98 RNASEL (0.61) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL25912796 0.98 RNASEL (0.61) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL25912933 0.98 RNASEL (0.61) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL25584009 0.96 RNASEL (0.62) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL25584016 0.96 RNASEL (0.62) RNASELP2RY1P2RY2SRCP2RX1
SCHEMBL26622399 0.95 RNASEL (0.59) RNASELP2RY1P2RY2SRCP2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215043-A1 RNA CAP ANALOGS AND METHODS OF USE MEDICI THERAPEUTICS, INC. 2025-07-03 US disclosed
US-20250026779-A1 ETHYL MODIFIED RNA CAPS AND METHODS OF USE MEDICI THERAPEUTICS, INC. 2025-01-23 US disclosed
WO-2023235362-A1 RNA CAP ANALOGS AND METHODS OF USE NUTCRACKER THERAPEUTICS, INC. (US) 2023-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215043-A1 RNA CAP ANALOGS AND METHODS OF USE RNGTT, RNMT, NSUN2 RNASEL 68/4885P2RY1 3218/4885P2RY2 3925/4885
US-20250026779-A1 ETHYL MODIFIED RNA CAPS AND METHODS OF USE RNGTT, RNMT, NSUN2 RNASEL 40/4885P2RY1 2798/4885P2RY2 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.